Washington University School of Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Washington University School of Medicine sits in the top decile of US sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count).
Washington University School of Medicine: 1,502 sponsored US clinical trials, 214 recruiting.
Washington University School of Medicine sponsors 1,502 registered US clinical trials on ClinicalTrials.gov, 214 of them currently recruiting, and 919 completed. 98 of these trials are in Phase 3-4 (later-stage) and 569 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 20 trials.
Top-decile sponsor footprint
Washington University School of Medicine ranks in the top decile of sponsors by registered trial count (#12 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
919 of 1,159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,502 total, page 6 of 31
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
NCT04331041
Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma
NCT04849871
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
NCT04643379
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
NCT04791839
Elevating Voices, Addressing Depression, Toxic Stress and Equity in Group Prenatal Care
NCT04838210
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
NCT04462328
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
NCT04699786
Personalizing Exercise for Parkinson Disease
NCT04782518
Study to Understand Risk and Resilience Opportunity for Newborns After Delivery
NCT04438161
Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
NCT04611880
Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine
NCT04206059
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
NCT04680910
Psychosocial Syndemics of Heart Failure
NCT04637776
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
NCT04551430
RESTORE Declined Livers Study
NCT04483102
Cabozantinib in High Grade Neuroendocrine Neoplasms
NCT04412629
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
NCT04331067
CET- REM (Correlating ECT Response to EEG Markers)
NCT04451135
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
NCT04331119
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
NCT04015700
Non-Operative Management and Early Response Assessment in Rectal Cancer
NCT03904043
Nerve Transfer After Spinal Cord Injury- Multi-center
NCT04023591
Identification of Predictors for Clinical Outcomes in Femoroacetabular Impingement Surgery
NCT04243447
AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
NCT04263181
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
NCT04046575
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
NCT03940209
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT03955978
Precision Nutrition and Metabolic Function
NCT04131166
RANKL Inhibition and Mammographic Breast Density
NCT04067726
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT03650764
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
NCT03921008
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
NCT03687957
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
NCT03572764
Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"
NCT03621696
Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma
NCT03612648
Spinraza in Adult Spinal Muscular Atrophy
NCT03709784
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
NCT03250247
Response Assessment in SB CD
NCT03646708
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
NCT03389477
Proton Beam Therapy in the Treatment of Esophageal Cancer
NCT03482791
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
NCT03030261
Group Versus Traditional Prenatal Care for Diabetes
NCT03301792
Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics
NCT03348280
Postprandial Nutrient Homeostasis Before and After Weight Loss Induced by Low-calorie Diet or RYGB
NCT03091725
Adaptive tDCS for Treatment-Resistant MDD
NCT02942368
Pediatric Urology Recovery After Surgery Endeavor (PURSUE)
NCT03245242
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
NCT02782546
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
NCT02756962
Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health
NCT02706262
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
NCT02611180
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 332 |
| Phase 2 | 237 |
| Phase 3 | 40 |
| Phase 4 | 58 |
Therapeutic Areas
What is open in the Washington University School of Medicine pipeline
214 recruiting of 1,502 indexed (14% open); 919 completed (61%).
Phase mix: 98 late (III/IV) vs 569 early (I/II) (early-phase heavy).
Top condition: Obesity (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Washington University School of Medicine: open-pipeline peers nationwide
Peers matched on 1,502 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Washington University School of Medicine sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,502 trials (± recruiting share)
- Yale University · 1,492 trials · 17% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Washington University School of Medicine page
1,502 registered trials is a research-attention snapshot, not an endorsement of Washington University School of Medicine or any single study.
- 214 of Washington University School of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Washington University School of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Washington University School of Medicine pipeline card: 1,502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.